Sorry if I missed this and/or it has been discussed but I just got this in my email and would like to know what it is about, the name of the stock and how it impacts ACTC.
Tap Into The $64 Billion Stem Cell Market
By Patrick Cox
One company’s stock is grossly underrated these days, as are many small-cap biotechs. Market psychology often disguises the long-term value of a company.
In my opinion,there is no company that has a bigger platform and a more undervalued stock... The platform is nonembryonic human parthenogenetic (often shortened to “parthenogenic”) stem cells (hpSCs). The company in question developed a way to make pluripotent stem cells using unused oocytes (immature unfertilized ova or eggs) gathered in the process of in vitro fertilization.
As a result, it owns the intellectual property on these remarkable cells.
There a number of advantages inherent in these hpSCs. One is that those who are opposed to the use of embryonic cells in therapies need not worry.
Cells made from these lines could be manufactured and kept ready for use at any time. Once you have determined your cell type, like your blood types, you could buy specific stem cells “off the shelf” for whatever purpose you have. And, in most cases, the differentiated hpSCs could be used with little or no immune suppression.
Some people believe that the actual number of hpSC lines needed to treat 85% of all humans is as few as ten. The company is in the process right now of finding the right oocyte donors and creating those hpSC lines.
10 Million Blind Regain Sight
In the 21st Century, a new dawn of medicine has emerged that could soon restore the sight of 10 million people worldwide. It’s a medical breakthrough that is unprecedented in human history. In fact, this amazing technology could eventually improve... and extend... every life of every person on earth.
And one tiny California Company, priced under 80 cents per stock, is at the forefront of this revolutionary medical treatment.
Click here to get the full details on this explosive penny stock that could significantly advance the field of regenerative medicine — and possibly make you ridiculously rich.
Currently, the company is moving ahead in four principal areas: retinal, corneal, liver and neural cells. The eye tissues will, I suspect, come to market first. There are tens of millions of people in Asia whose sight could be restored if they had access to transplant eye tissues. Because the infrastructure for organ donations does not exist, however, Asian scientists are enormously excited about bringing hpSC retinal and corneal tissues to their populations.
While growing parthenogenic corneal stem cells for research purposes, beautiful sphere or orbs of human eye tissue formed spontaneously, pointing to the power of these stem cells.
Though no one had set out to produce artificial eyes for the purpose of product testing, it was an obvious possibility. Draize testing is a method for testing chemicals used in all kinds of products, from cosmetics and cleaning supplies to drugs and perfumes, for human safety. The actual procedure involves applying the chemicals to living animals’ eyes. Then, the eyes are often removed for testing.
Tests performed indicate that the hpSCs perform as well as, if not better than, animal eyes as a predictor for toxicity. This isn’t surprising, as the orbs are living human cells.
Needless to say, this is an important milestone, as Draize testing is currently a multibillion-dollar industry and everyone would like to see the procedure minimized. If animal lovers realize that there is now an alternative, I think the pressure to buy corneal orbs will be significant...
Yours for transformational profits,
Patrick Cox
P.S. I’ve been closely following the 50 cent company behind this important research. However, it’s simply too small and thinly traded to be revealed to such a large audience. But if you want to learn more about the potential of its stem cell discovery simply click here.
Tap Into The $64 Billion Stem Cell Market is featured at Penny Sleuth.
--------------------------------------------------------------------------------
The Secret $200 Retirement Blueprint
Investing in Penny Stocks
What Is Technical Trading
--------------------------------------------------------------------------------
Follow the Penny Sleuth on Twitter, here.
Become a Facebook Fan of The Penny Sleuth, here.
The Penny Sleuth, a free e-letter, offers independent news and commentary on small cap stocks, options and high growth opportunities. We sent this e-mail to elysse1@msn.com because you or someone using your e-mail address subscribed to this service.
Are you having trouble receiving your Penny Sleuth? You can ensure its arrival in your mailbox by: Whitelisting Penny Sleuth.
--------------------------------------------------------------------------------
To end your Penny Sleuth e-mail subscription, click: Unsubscribe.
--------------------------------------------------------------------------------
AI
